154 related articles for article (PubMed ID: 36939378)
21. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
22. Two well-differentiated pancreatic neuroendocrine tumor mouse models.
Wong C; Tang LH; Davidson C; Vosburgh E; Chen W; Foran DJ; Notterman DA; Levine AJ; Xu EY
Cell Death Differ; 2020 Jan; 27(1):269-283. PubMed ID: 31160716
[TBL] [Abstract][Full Text] [Related]
23. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
[TBL] [Abstract][Full Text] [Related]
24. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
[TBL] [Abstract][Full Text] [Related]
25. Diagnosing pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1 in daily practice.
van Beek DJ; Pieterman CRC; Wessels FJ; van de Ven AC; de Herder WW; Dekkers OM; Zandee WT; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
Front Endocrinol (Lausanne); 2022; 13():926491. PubMed ID: 36277719
[TBL] [Abstract][Full Text] [Related]
26. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice.
Fuentes ME; Lu X; Flores NM; Hausmann S; Mazur PK
Sci Rep; 2024 Apr; 14(1):8510. PubMed ID: 38609433
[TBL] [Abstract][Full Text] [Related]
27. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic imaging in MEN1-comparison of conventional and somatostatin receptor positron emission tomography/computed tomography imaging in real-life setting.
Kostiainen I; Majala S; Schildt J; Parviainen H; Kauhanen S; Seppänen H; Miettinen PJ; Matikainen N; Ryhänen EM; Schalin-Jäntti C
Eur J Endocrinol; 2023 May; 188(5):421-429. PubMed ID: 36943311
[TBL] [Abstract][Full Text] [Related]
29. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients.
Speisky D; Duces A; Bièche I; Rebours V; Hammel P; Sauvanet A; Richard S; Bedossa P; Vidaud M; Murat A; Niccoli P; Scoazec JY; Ruszniewski P; Couvelard A;
Clin Cancer Res; 2012 May; 18(10):2838-49. PubMed ID: 22461457
[TBL] [Abstract][Full Text] [Related]
30. Dynamic epigenetic regulation by menin during pancreatic islet tumor formation.
Lin W; Watanabe H; Peng S; Francis JM; Kaplan N; Pedamallu CS; Ramachandran A; Agoston A; Bass AJ; Meyerson M
Mol Cancer Res; 2015 Apr; 13(4):689-98. PubMed ID: 25537453
[TBL] [Abstract][Full Text] [Related]
31. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
32. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
33. Placenta-Specific 8 Is Overexpressed and Regulates Cell Proliferation in Low-Grade Human Pancreatic Neuroendocrine Tumors.
Tatura M; Schmidt H; Haijat M; Stark M; Rinke A; Diels R; Lawlor RT; Scarpa A; Schrader J; Hackert T; Schimmack S; Gress TM; Buchholz M
Neuroendocrinology; 2020; 110(1-2):23-34. PubMed ID: 31018208
[TBL] [Abstract][Full Text] [Related]
34. A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective.
Werle SD; Ikonomi N; Lausser L; Kestler AMTU; Weidner FM; Schwab JD; Maier J; Buchholz M; Gress TM; Kestler AMR; Kestler HA
NPJ Syst Biol Appl; 2023 Jun; 9(1):22. PubMed ID: 37270586
[TBL] [Abstract][Full Text] [Related]
35. Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitment.
Lee E; O'Keefe S; Leong A; Park HR; Varadarajan J; Chowdhury S; Hiner S; Kim S; Shiva A; Friedman RA; Remotti H; Fojo T; Yang HW; Thurston G; Kim M
J Clin Invest; 2023 Oct; 133(20):. PubMed ID: 37843277
[TBL] [Abstract][Full Text] [Related]
36. Targeting HDACs in Pancreatic Neuroendocrine Tumor Models.
Schmitz RL; Weissbach J; Kleilein J; Bell J; Hüttelmaier S; Viol F; Clauditz T; Grabowski P; Laumen H; Rosendahl J; Michl P; Schrader J; Krug S
Cells; 2021 Jun; 10(6):. PubMed ID: 34204116
[TBL] [Abstract][Full Text] [Related]
37. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract][Full Text] [Related]
38. Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets.
Lin W; Francis JM; Li H; Gao X; Pedamallu CS; Ernst P; Meyerson M
Cancer Biol Ther; 2016 Dec; 17(12):1274-1281. PubMed ID: 27801610
[TBL] [Abstract][Full Text] [Related]
39. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
[TBL] [Abstract][Full Text] [Related]
40. Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors.
Lakiza O; Lutze J; Vogle A; Williams J; Abukdheir A; Miller P; Liao C'; Pitroda SP; Martinez C; Olivas A; Setia N; Kron SJ; Weichselbaum RR; Keutgen XM
Endocr Relat Cancer; 2022 Mar; 29(4):225-239. PubMed ID: 35171113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
